| Autor: |
Horiuchi Y; Division of Genetic Counseling, Genetic Medicine Promotion, Shizuoka Cancer Center Hospital, Shizuoka, Japan.; Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan., Matsubayashi H; Division of Genetic Counseling, Genetic Medicine Promotion, Shizuoka Cancer Center Hospital, Shizuoka, Japan. h.matsubayashi@scchr.jp., Kiyozumi Y; Division of Genetic Counseling, Genetic Medicine Promotion, Shizuoka Cancer Center Hospital, Shizuoka, Japan., Nishimura S; Division of Genetic Counseling, Genetic Medicine Promotion, Shizuoka Cancer Center Hospital, Shizuoka, Japan., Higashigawa S; Division of Genetic Counseling, Genetic Medicine Promotion, Shizuoka Cancer Center Hospital, Shizuoka, Japan., Kado N; Division of Genetic Counseling, Genetic Medicine Promotion, Shizuoka Cancer Center Hospital, Shizuoka, Japan., Nagashima T; Research Institute of Shizuoka Cancer Center, Shizuoka, Japan., Mizuguchi M; Research Institute of Shizuoka Cancer Center, Shizuoka, Japan., Ohnami S; Research Institute of Shizuoka Cancer Center, Shizuoka, Japan., Arai M; Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan., Urakami K; Research Institute of Shizuoka Cancer Center, Shizuoka, Japan., Kusuhara M; Research Institute of Shizuoka Cancer Center, Shizuoka, Japan., Yamaguchi K; Research Institute of Shizuoka Cancer Center, Shizuoka, Japan. |
| Abstrakt: |
High-throughput sequencing has greatly contributed to precision medicine. However, challenges remain in reporting secondary findings (SFs) of germline pathogenic variants and managing the affected patients. The aim of this study was to examine the incidence of SFs in Japanese cancer patients using whole exome sequencing (WES) and to understand patient preferences regarding SF disclosure. WES was conducted for 2480 cancer patients. Genomic data were screened and classified for variants of 59 genes listed by the American College of Medical Genetics and Genomics SF v2.0 and for an additional 13 hereditary cancer-related genes. Majority of the participants (68.9%; 1709/2480) opted for disclosure of their SFs. Thirty-two pathogenic or likely pathogenic variants, including BRCA1 (7 patients), BRCA2 (4), CHEK2 (4), PTEN (3), MLH1 (3), SDHB (2), MSH6 (1), NF1 (1), EXT2 (1), NF1 (1), NTRK1 (1), MYH7 (3), MYL2 (1), TNNT2 (1), LDLR (2), FBN1 (1), and KCNH2 (1) were recognized in 36 patients (1.5%). Twenty-eight (77.8%) patients underwent genetic counseling and received their SF results. Eighteen (64.3%) patients underwent clinical management for SFs. Genetic validation tests were administered significantly more frequently to patients with than without a SF-related personal history (P = 0.025). This was a first attempt at a large-scale systematic exome analysis in Japan; nevertheless, many cancer patients opted for disclosure of SFs and accepted or considered clinical management. |
Full text from SpringerLink